



10550518 - GAU: 1633

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|---|--------------------------|--------------------------------|
| Substitute for Form 1449A/P (08-03) | | Complete if Known | |
| | | Application Number | 10/550,518 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Filing Date | § 371 Date: September 26, 2005 |
| | | First Named Inventor | BACHMANN, Martin F. |
| | | Art Unit | 1633 |
| | | Examiner Name | LI, Qian Janice |
| | | Attorney Docket Number | 1700.0630000/BJD/WBC |
| Sheet | 1 | of | 5 |

Duplicate

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|--|--------------------------------|---|---|
| | | Number-Kind Code ² (if known) | | | |
| | AG3 | US- 5,057,540 | 10/15/1991 | Kensil <i>et al.</i> | |
| | AH3 | US- 5,071,651 | 12/10/1991 | Sabara <i>et al.</i> | |
| | AI3 | US- 5,374,426 | 12/20/1994 | Sabara <i>et al.</i> | |
| | AJ3 | US- 5,962,636 | 10/05/1999 | Bachmaier <i>et al.</i> | |
| | AK3 | US- 5,989,868 | 11/23/1999 | Harrison <i>et al.</i> | |
| | AK4 | US- 6,949,520 B1 | 09/27/2005 | Hartmann <i>et al.</i> | |
| | AB4 | US- 2001/0044416 A1 | 11/22/2001 | McCluskie <i>et al.</i> | |
| | AC4 | US- 2003/0050268 A1 | 03/13/2003 | Krieg <i>et al.</i> | |
| | AD4 | US- 2003/0050263 A1 | 03/13/2003 | Krieg <i>et al.</i> | |
| | AE4 | US- 2003/0060440 A1 | 03/27/2003 | Klinman <i>et al.</i> | |
| | AF4 | US- 2003/0087848 A1 | 05/08/2003 | Bratzler <i>et al.</i> | |
| | AG4 | US- 2003/0099668 A1 | 05/29/2003 | Bachmann <i>et al.</i> | |
| | AH4 | US- 2004/0005338 A1 | 01/08/2004 | Bachmann <i>et al.</i> | |
| | AI4 | US- 2005/0101557 A1 | 05/12/2005 | Krieg <i>et al.</i> | |
| | AJ4 | US- 2005/0169888 A1 | 08/04/2005 | Hartmann <i>et al.</i> | |
| | AK4 | US- 2006/0286070 A1 | 12/21/2006 | Hartmann <i>et al.</i> | |
| | | | | | |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | † |
| | | Country Code* Kind Code ⁵ (if known) | | | | |
| | AP9 | EP 0 468 520 A2 | 01/29/1992 | Tokunaga <i>et al.</i> | | |
| | AL10 | WO 94/02499 A1 | 02/03/1994 | Padmapriya <i>et al.</i> | | |
| | AM10 | WO 95/26204 A1 | 10/05/1995 | Hutcherson <i>et al.</i> | | |
| | AN10 | WO 96/02555 A1 | 02/01/1996 | Krieg | | |
| | AO10 | EP 0 772 619 B1 | 05/14/1997 | Krieg <i>et al.</i> | | |
| | AP10 | WO 97/28259 A1 | 08/07/1997 | Carson <i>et al.</i> | | |

| | | |
|--------------------|-----------------------------|-----------------|
| Examiner Signature | /Q. Janice LI/ (07/01/2008) | Date Considered |
|--------------------|-----------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | |
|------------------------|----------------------|
| Attorney Docket Number | 1700.0630000/H3D/WBC |
|------------------------|----------------------|

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /qjl/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|-------|---|----|---|------------------------|-----------------------|
| Sheet | 3 | of | 5 | Attorney Docket Number | 1700.06300000-BJD/WBC |
|-------|---|----|---|------------------------|-----------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 501.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete If Known

| | |
|------------------------|--------------------------------|
| Application Number | 10/550,518 |
| Filing Date | § 371 Date: September 26, 2005 |
| First Named Inventor | BACHMANN, Martin F. |
| Art Unit | 1633 |
| Examiner Name | Li, Qian Janice |
| Attorney Docket Number | 1790.0630000/BJD/WBC |

| | | | | | |
|-------|---|----|---|------------------------|-----------------------|
| Sheet | 4 | of | 5 | Attorney Docket Number | 1700.06300000/BJD/WBC |
|-------|---|----|---|------------------------|-----------------------|

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | 7 ⁶ |
| | | Country Code ² Kind Code ³ (in known) | | | | |
| | AN13 | WO 00/23955 A1 | 04/27/2000 | Schiller <i>et al.</i> | | |
| | AO13 | WO 02/10416 A1 | 02/07/2002 | Gowans <i>et al.</i> | | |
| | AP13 | WO 03/030656 A2 | 04/17/2003 | Babiuk <i>et al.</i> | | |
| | AL14 | WO 03/040308 A2 | 05/15/2003 | Klinman <i>et al.</i> | | |
| | AM14 | WO 03/045431 A2 | 06/05/2003 | Vicari <i>et al.</i> | | |
| | AN14 | WO 2004/009124 A2 | 01/29/2004 | Bachmann <i>et al.</i> | | |

| | | |
|--------------------|-----------------------------|-----------------|
| Examiner Signature | /Q. Janice Li/ (07/01/2008) | Date Considered |
|--------------------|-----------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTC-9199 and select option 2.

792296_1.DOC

Rev. 11-03-03 syb

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /qjl/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|-------|---|----|---|------------------------|-----------------------|
| Sheet | 5 | of | 5 | Attorney Docket Number | 1700.06300000/BJD/WBC |
|-------|---|----|---|------------------------|-----------------------|

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with request for prior art. *Applicant or non-citizen designer number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|-----------------|--------------------------|--------------------------------|------------------------|----------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete If Known | | | |
| | | Application Number | 10/550,518 | | |
| | | Filing Date | § 371 Date: September 26, 2005 | | |
| | | First Named Inventor | BACHMANN, Martin P. | | |
| | | Art Unit | 1633 | | |
| Examiner Name | Li, Qian Janice | | | | |
| Sheet | 1 | of | 8 | Attorney Docket Number | 1700 0630000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | NPL103 | Allison (1994) Int J Technol Assess Health Care 10(1):107-20 -- Adjuvants and immune enhancement. Cambridge University Press | |
| | NPL104 | Ballas, <i>et al.</i> (1996) J Immunol 157(5):1840-5 -- Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. The American Association of Immunologists | |
| | NPL105 | Bartholomé, <i>et al.</i> (1999) J Interferon Cytokine Res 19(5):471-8 -- IFN- β interferes with the differentiation of dendritic cells from peripheral blood mononuclear cells: selective inhibition of CD40-dependent interleukin-12 secretion. Mary Ann Liebert, Inc. | |
| | NPL106 | Beaucage, <i>et al.</i> (1981) Tet Lett 22(20):1859-62 -- Deoxynucleoside Phosphoramidites-A New Class of Key Intermediates for Deoxypolynucleotide Synthesis. Pergamon Press Ltd. | |
| | NPL107 | Blackwell, <i>et al.</i> (April 2003) J Immunol 170(8):4061-8 -- CpG-A-induced monocyte IFN- γ -inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN- α . The American Association of Immunologists, Inc. | |
| | NPL108 | Bousquet, <i>et al.</i> (1998) J Allergy Clin Immunol 102(4 Pt 1):558-62 -- Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Mosby, Inc. | |
| | NPL109 | Branda, <i>et al.</i> (1996) J Lab Clin Med 128(3):329-38 -- Amplification of antibody production by phosphorothioate oligodeoxynucleotides. Mosby-Year Book, Inc. | |
| | NPL110 | Cella, <i>et al.</i> (1999) Nat Med 5(8):919-23 -- Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nature America Inc. | |
| | NPL111 | Cella, <i>et al.</i> (1999) J Exp Med 189(5):821-9 -- Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. The Rockefeller University Press | |
| | NPL112 | Choi, <i>et al.</i> (2000) Virology 275(2):249-57 -- Packaging of tobacco mosaic virus subgenomic RNAs by Brome mosaic virus coat protein exhibits RNA controlled polymorphism. Academic Press | |

| | | | |
|--------------------|-----------------------------|-----------------|--|
| Examiner Signature | /Q. Janice Li/ (07/01/2008) | Date Considered | |
|--------------------|-----------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|--------------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/550,518 |
| | | | | Filing Date | § 371 Date: September 26, 2005 |
| | | | | First Named Inventor | BACHMANN, Martin F. |
| | | | | Art Unit | 1633 |
| | | | | Examiner Name | L.J. Qian Janice |
| Sheet | 2 | of | 8 | Attorney Docket Number | 1700 0630000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published | | T ² |
| | NPL113 | Choi, <i>et al.</i> (January 2002) Proc Natl Acad Sci U S A 99(2):655-60 -- tRNA elements mediate the assembly of an icosahedral RNA virus. National Academy of Sciences | | |
| | NPL114 | Clark, <i>et al.</i> (2001) J Gen Virol 82(Pt 11):2791-7 -- Immunity against both polyomavirus VP1 and a transgene product induced following intranasal delivery of VP1 pseudocapsid-DNA complexes. Society for General Microbiology | | |
| | NPL115 | Cooper, <i>et al.</i> (August 2004) Vaccine 22(23-24):3136-43 -- Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Elsevier Ltd. | | |
| | NPL116 | Dalpke, <i>et al.</i> (February 2002) Immunology 106(1):102-12 -- Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides <i>in vitro</i> and <i>in vivo</i> . Blackwell Science Ltd. | | |
| | NPL117 | Gavett, <i>et al.</i> (1995) J Exp Med 182(5):1527-36 -- Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. The Rockefeller University Press | | |
| | NPL118 | Goeckeritz, <i>et al.</i> (1999) Int Immunol 11(10):1693-700 -- Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotide motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion. Oxford University Press | | |
| | NPL119 | Gursel, <i>et al.</i> (2001) J Immunol 167(6):3324-8 -- Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. The American Association of Immunologists | | |
| | NPL120 | Häcker, <i>et al.</i> (1998) EMBO J 17(21):6230-40 -- CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. Oxford University Press | | |
| | NPL121 | Halperin, <i>et al.</i> (June 2003) Vaccine 21(19-20):2461-7 -- A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Elsevier Science Ltd. | | |
| | NPL122 | Halpern, <i>et al.</i> (1996) Cell Immunol 167(1):72-8 -- Bacterial DNA induces murine interferon- γ production by stimulation of interleukin-12 and tumor necrosis factor- α . Academic Press, Inc. | | |

| | | | |
|--------------------|-----------------------------|-----------------|--|
| Examiner Signature | /Q. Janice Li/ (07/01/2008) | Date Considered | |
|--------------------|-----------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|--------------------------|---------------------------------|------------------------|----------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete If Known | | | |
| | | Application Number | 10/550,518 | | |
| | | Filing Date | \$ 371 Date: September 26, 2005 | | |
| | | First Named Inventor | BACHMANN, Martin F. | | |
| | | Art Unit | 1633 | | |
| | | Examiner Name | LI, Qian Janice | | |
| Sheet | 3 | of | 8 | Attorney Docket Number | 1700.0630000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | NPL123 | Hartmann, <i>et al.</i> (2000) J Immunol 164(2):944-52 -- Mechanism and function of a newly identified CpG DNA motif in human primary B cells. The American Association of Immunologists | |
| | NPL124 | Hartmann, <i>et al.</i> (1999) Proc Natl Acad Sci U S A 96(16):9305-10 -- CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. National Academy of Sciences | |
| | NPL125 | Heal, <i>et al.</i> (2000) Vaccine 18:251-8 -- Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids. Elsevier Science Ltd. | |
| | NPL126 | Heath (1994) Cancer Biother 9(1):1-6 -- Cytokines and the rational choice of immunological adjuvants. Mary Ann Liebert, Inc. | |
| | NPL127 | Hsu, <i>et al.</i> (1996) Nat Med 2(5):540-4 -- Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness <i>in vivo</i> by genetic immunization. Nature Publishing Group | |
| | NPL128 | Iho, <i>et al.</i> (1999) J Immunol 163(7):3642-52 -- Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN- γ production <i>in vitro</i> . The American Association of Immunologists | |
| | NPL129 | Jiang, <i>et al.</i> (1999) Vaccine 17(7-8):1005-13 -- Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Elsevier Science Ltd. | |
| | NPL130 | Jiang, <i>et al.</i> (1999) Hum Gene Ther 10(16):2627-36 -- A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide. Mary Ann Liebert, Inc. | |
| | NPL131 | Joelson, <i>et al.</i> (1997) J Gen Virol 78:1213-7 -- Presentation of a foreign peptide on the surface of tomato bushy stunt virus. Society for General Microbiology | |
| | NPL132 | Kerkmann, <i>et al.</i> (May 2003) J Immunol 170(9):4465-74 -- Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. The American Association of Immunologists, Inc. | |

| | | | |
|--------------------|-----------------------------|-----------------|--|
| Examiner Signature | /Q. Janice Li/ (07/01/2008) | Date Considered | |
|--------------------|-----------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|--------------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/550,518 |
| | | | | Filing Date | § 371 Date: September 26, 2005 |
| | | | | First Named Inventor | BACHMANN, Martin F. |
| | | | | Art Unit | 1633 |
| | | | | Examiner Name | LJ, Qian Janice |
| Sheet | 4 | of | 8 | Attorney Docket Number | 1700.0630000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | NPL133 | Kline, <i>et al.</i> (1998) <i>J Immunol</i> 160(6):2555-9 -- Cutting Edge: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. The American Association of Immunologists | |
| | NPL134 | Kline, <i>et al.</i> (February 2002) <i>Am J Physiol Lung Cell Mol Physiol</i> 283(1):L170-9 -- Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. The American Physiological Society | |
| | NPL135 | Klinman (April 2004) <i>Nat Rev Immunol</i> 4(4):249-58 -- Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Publishing Group | |
| | NPL136 | Klinman, <i>et al.</i> (1996) <i>Proc Natl Acad Sci U S A</i> 93(7):2879-83 -- CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ . National Academy of Sciences | |
| | NPL137 | Klinman, <i>et al.</i> (July 2004) <i>Vaccine</i> 22(21-22):2881-6 -- CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Elsevier Ltd. | |
| | NPL138 | Krieg (1999) <i>Biochim Biophys Acta</i> 1489(1):107-16 -- Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Elsevier Science B.V. | |
| | NPL139 | Krieg (October 2002) <i>Annu Rev Immunol</i> 20:709-60 -- CpG motifs in bacterial DNA and their immune effects. Annual Reviews | |
| | NPL140 | Krieg, <i>et al.</i> (2001) <i>Curr Opin Mol Ther</i> 3(1):15-24 -- Enhancing vaccines with immune stimulatory CpG DNA. PharmaPress Ltd. | |
| | NPL141 | Krieg, <i>et al.</i> (1995) <i>Nature</i> 374(6522):546-9 -- CpG motifs in bacterial DNA trigger direct B-cell activation. Nature Publishing Group | |
| | NPL142 | Krieg, <i>et al.</i> (1996) <i>Antisense Nucleic Acid Drug Dev</i> 6(2):133-9 -- Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Mary Ann Liebert, Inc. | |

| | | | |
|--------------------|-----------------------------|-----------------|--|
| Examiner Signature | /Q. Janice LJ/ (07/01/2008) | Date Considered | |
|--------------------|-----------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|--------------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/550,318 |
| | | | | Filing Date | § 371 Date: September 26, 2005 |
| | | | | First Named Inventor | BACHMANN, Martin F. |
| | | | | Art Unit | 1633 |
| | | | | Examiner Name | LI, Qian Janice |
| Sheet | 5 | of | 8 | Attorney Docket Number | 1700.0630000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|----------|---|----------------|--|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published | T ² | |
| | NPL143 | Krug, <i>et al.</i> (April 2003) <i>J Immunol</i> 170(7):3468-77 -- CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. The American Association of Immunologists, Inc. | | |
| | NPL144 | Lechner, <i>et al.</i> (January 2002) <i>Intervirology</i> 45(4-6):212-7 -- Virus-like particles as a modular system for novel vaccines. S. Karger AG, Basel | | |
| | NPL145 | Lee, <i>et al.</i> (2000) <i>J Immunol</i> 165(7):3631-9 -- Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. The American Association of Immunologists | | |
| | NPL146 | Leibl, <i>et al.</i> (1998) <i>Vaccine</i> 16(4):340-5 -- Adjuvant/carrier activity of inactivated tick-borne encephalitis virus. Elsevier Science Ltd. | | |
| | NPL147 | Liljas, <i>et al.</i> (1994) <i>J Mol Biol</i> 244(3):279-90 -- Crystal structure of bacteriophage fr capsids at 3.5 Å resolution. Academic Press Limited | | |
| | NPL148 | Liu, <i>et al.</i> (1998) <i>Blood</i> 92(10):3730-6 -- Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. The American Society of Hematology | | |
| | NPL149 | Luo, <i>et al.</i> (1998) <i>Virology</i> 240(2):316-25 -- Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120. Academic Press | | |
| | NPL150 | Mahon (2001) <i>Curr Med Chem</i> 8(9):1057-75 -- The rational design of vaccine adjuvants for mucosal and neonatal immunization. Bentham Science Publishers Ltd. | | |
| | NPL151 | Notka, <i>et al.</i> (2000) <i>Vaccine</i> 18(3-4):291-301 -- Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies. Elsevier Science Ltd. | | |
| | NPL152 | Oxenius, <i>et al.</i> (1999) <i>J Virol</i> 73(5):4120-6 -- CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. American Society for Microbiology | | |

| | | | |
|--------------------|-----------------------------|-----------------|--|
| Examiner Signature | /Q. Janice LI/ (07/01/2008) | Date Considered | |
|--------------------|-----------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|--------------------------|--------------------------------|------------------------|----------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete If Known | | | |
| | | Application Number | 10/550,518 | | |
| | | Filing Date | § 371 Date: September 26, 2005 | | |
| | | First Named Inventor | BACHMANN, Martin F. | | |
| | | Art Unit | 1633 | | |
| | | Examiner Name | LI, Qian Janice | | |
| Sheet | 6 | of | 8 | Attorney Docket Number | 1700.0630000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | NPL153 | Pestka (1986) Methods Enzymol 119:14-23 -- Interferon standards and general abbreviations. Academic Press, Inc. | |
| | NPL154 | Pisetsky, <i>et al.</i> (1994) Life Sci 54(2):101-7 -- Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Pergamon Press Ltd. | |
| | NPL155 | Pushko, <i>et al.</i> (1993) Protein Eng 6(8):883-91 -- Analysis of RNA phage <i>φ</i> coat protein assembly by insertion, deletion and substitution mutagenesis. Oxford University Press | |
| | NPL156 | Raz (1997) Springer Semin Immunopathol 19(2):131-7 -- Introduction: gene vaccination, current concepts and future directions. Springer-Verlag | |
| | NPL157 | Raz, <i>et al.</i> (1996) Proc Natl Acad Sci U S A 93(10):5141-5 -- Preferential induction of a Th ₁ immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. National Academy of Sciences | |
| | NPL158 | Sato, <i>et al.</i> (1996) Science 273(5273):352-4 -- Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. American Association for the Advancement of Science | |
| | NPL159 | Schwarz, <i>et al.</i> (June 2003) Eur J Immunol 33(6):1465-70 -- Role of Toll-like receptors in costimulating cytotoxic T cell responses. WILEY-VCH Verlag GMBH & Co. | |
| | NPL160 | Serre, <i>et al.</i> (1998) J Immunol 161(11):6059-67 -- Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. The American Association of Immunologists | |
| | NPL161 | Siegal, <i>et al.</i> (1999) Science 284(5421):1835-7 -- The nature of the principal type 1 interferon-producing cells in human blood. American Association for the Advancement of Science | |
| Duplicate | NPL162 | Stormi, <i>et al.</i> (February 2004) J Immunol 172(3):1777-85 -- Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. The American Association of Immunologists, Inc. | |

| | | | |
|--------------------|-----------------------------|-----------------|--|
| Examiner Signature | /Q. Janice LI/ (07/01/2008) | Date Considered | |
|--------------------|-----------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | | |
|--|---|----|---|--------------------------|--------------------------------|----------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | | |
| | | | | Application Number | 10/550,518 | |
| | | | | Filing Date | § 371 Date: September 26, 2005 | |
| | | | | First Named Inventor | BACHMANN, Martin F. | |
| | | | | Art Unit | 1633 | |
| | | | | Examiner Name | LI, Qian Janice | |
| Sheet | 7 | of | 8 | Attorney Docket Number | | 1700.0630000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published | | T ² |
| | NPL163 | Takauji, <i>et al.</i> (November 2002) J Leukoc Biol 72(5):1011-9 -- CpG-DNA-induced IFN- α production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors. Wiley-Liss | | |
| | NPL164 | Tars, <i>et al.</i> (1997) J Mol Biol 271(5):759-73 -- The crystal structure of bacteriophage GA and a comparison of bacteriophages belonging to the major groups of <i>Escherichia coli</i> leviviruses. Academic Press Limited | | |
| | NPL165 | Uhlmann, <i>et al.</i> (March 2003) Curr Opin Drug Discov Devel 6(2):204-17 -- Recent advances in the development of immunostimulatory oligonucleotides. Current Drugs | | |
| | NPL166 | Van Ojik, <i>et al.</i> (October 2002) Ann. Oncol. 13:157-158 "Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors," Oxford University Press, Abstract No. 5790 | | |
| | NPL167 | Verthelyi, <i>et al.</i> (2001) J Immunol 166(4):2372-7 -- Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. The American Association of Immunologists | | |
| | NPL168 | Verthelyi, <i>et al.</i> (April 2004) AIDS 18(7):1003-8 -- CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. Lippincott Williams & Wilkins | | |
| | NPL169 | Vrtala, <i>et al.</i> (1998) J Immunol 160(12):6137-44 -- Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. The American Association of Immunologists | | |
| | NPL170 | Warnes, <i>et al.</i> (1995) Gene 160(2):173-8 -- Expression of the measles virus nucleoprotein gene in <i>Escherichia coli</i> and assembly of nucleocapsid-like structures. Elsevier Science B.V. | | |
| | NPL171 | Weiner, G., (2000) "Declaration of Dr. George Weiner Under 37 CFR §1.32," submitted in support of US Application No. 09/286,098, 9 pages | | |
| | NPL172 | Weiner, <i>et al.</i> (1997) Proc Natl Acad Sci U S A 94(20):10833-7 -- Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. The National Academy of Sciences | | |

| | | | |
|--------------------|-----------------------------|-----------------|--|
| Examiner Signature | /Q. Janice Li/ (07/01/2008) | Date Considered | |
|--------------------|-----------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|--------------------------|--------------------------------|----------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10/550,518 | |
| | | | Filing Date | § 371 Date: September 26, 2005 | |
| | | | First Named Inventor | BACHMANN, Martin F. | |
| | | | Art Unit | 1633 | |
| | | | Examiner Name | LI, Qian Janice | |
| Sheet | 8 | of | 8 | Attorney Docket Number | 1700.0630000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|----------|---|--|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published | | T ² |
| | NPL173 | Yamamoto, <i>et al.</i> (1992) <i>J Immunol</i> 148(12):4072-6 -- Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. The American Association of Immunologists | | |
| | NPL174 | Yamamoto, <i>et al.</i> (1994) <i>Antisense Res Dev</i> 4(2):119-22 -- Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Mary Ann Liebert, Inc. | | |
| | NPL175 | Yamamoto, <i>et al.</i> (1994) <i>Jpn J Cancer Res</i> 85(8):775-9 -- Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes <i>in vitro</i> . Japanese Cancer Association | | |
| | NPL176 | Yamamoto, <i>et al.</i> (2000) <i>Springer Semin Immunopathol</i> 22(1-2):11-9 -- The discovery of immunostimulatory DNA sequence. Springer-Verlag | | |
| | NPL177 | Yu, <i>et al.</i> (September 2002) <i>Biochem Biophys Res Commun</i> 297(1):83-90 -- Potent CpG oligonucleotides containing phosphodiester linkages: <i>in vitro</i> and <i>in vivo</i> immunostimulatory properties. Elsevier Science (USA) | | |
| | NPL178 | Zlotnick, <i>et al.</i> (2000) <i>Virology</i> 277(2):450-6 -- Mechanism of capsid assembly for an icosahedral plant virus. Academic Press | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| | | | |
|--------------------|----------------------------|-----------------|--|
| Examiner Signature | /Q. Janice LI (07/01/2008) | Date Considered | |
|--------------------|----------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.